InterventionsHuman trial

ACCESS Trial: Dose-Ranging Evaluation of Aleniglipron, an Oral Small Molecule Nonpeptide GLP-1RA, Demonstrates Meaningful Weight Reductions in People Living with Obesity and Overweight

ADA Scientific Sessions 2026 Abstract

The paper

ROSENSTOCK J, RYAN D, ACOSTA A et al.

ADA Scientific Sessions 2026 Abstract · 5 Jun 2026

Presented at ADA Scientific Sessions 2026 · Oral 1032-OR

doi.org/10.2337/db26-1032-or

Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
The New England Journal of Medicine · 4 Oct 2026